

**Joint Conference of European Human
Pharmacological Societies**

11-12 April 2013 ~ Nice Sophia Antipolis FRANCE

CLUB PHASE 1




Lessons learned from late phase failures and successes

Introduction

Dr Yves Donazzolo and Dr Maikel Raghoobar

Diagnosing the decline in the pharmaceutical R&D efficiency




Jack W. Scannell - Alex Blanckley - Helen Boldon - Brian Warrington

PERSPECTIVES

Scannell et al, *Nature Reviews Drug Discovery*
11 (March 2012):191-200

Nature Reviews | Drug Discovery

Can the pharmaceutical industry reduce attrition rates?



Ismail Kola - John Landis


PERSPECTIVES

NATURE REVIEWS | DRUG DISCOVERY

I. Kola and J. Landis, *Nature Reviews Drug Discovery* 3 (2004): 711-715

How to improve R&D productivity: the pharmaceutical industry's grand challenge

THE QUICK WIN, FAST FAIL DRUG DEVELOPMENT PARADIGM




ANALYSIS

Steven M. Paul - Daniel S. Mytelka - Christopher T. Dunwiddie -
Charles C. Persinger - Bernard H. Munos - Stacy R. Lindborg - Aaron L. Schacht

NATURE REVIEWS | DRUG DISCOVERY

Complexity of Innovative Drug Development



Minimize bureaucracy
Invest in Technology & People
Identify tailor-made processes

“Business as usual” is not an option anymore

ANALYSIS

Published Lessons Learned to challenge our speakers

Improvements of clinical trial design, selection of drug targets, efficient execution of clinical trial design, etc.

Prioritize resources, avoid risks

Improve technical attrition
(translational target to medicine)

Develop/Hire experienced drug hunters
(every medicine had/has objectives to halt development)

CONCLUSION

How can Clinical Pharmacology contribute to reduce attrition rates?

Human patient data and identification of best indication in early clinical development

Tailoring for specific patient (sub)populations (pathology, genotype, etc.)

Introduce creativity in translational and clinical research

Speakers: what else?

CONCLUSION